Bionano Genomics, Inc.: income tax expense or benefit
Income tax expense or benefit for Bionano Genomics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Bionano Genomics, Inc. financial histories
What this measure means
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 67,000 | USD | 2026-03-23 | 10-K · 0001411690-26-000007 |
| 2024-01-01 | 2024-12-31 | 33,000 | USD | 2026-03-23 | 10-K · 0001411690-26-000007 |
| 2023-01-01 | 2023-12-31 | 62,000 | USD | 2025-03-31 | 10-K · 0001411690-25-000037 |
| 2022-01-01 | 2022-12-31 | 1,884,000 | USD | 2024-03-05 | 10-K · 0001411690-24-000013 |
| 2021-01-01 | 2021-12-31 | -5,717,000 | USD | 2023-03-09 | 10-K · 0001411690-23-000010 |
| 2020-01-01 | 2020-12-31 | 29,000 | USD | 2022-03-01 | 10-K · 0001411690-22-000007 |
| 2019-01-01 | 2019-12-31 | 21,048 | USD | 2021-03-23 | 10-K · 0001411690-21-000004 |
| 2018-01-01 | 2018-12-31 | 15,511 | USD | 2020-03-10 | 10-K · 0001411690-20-000006 |
| 2017-01-01 | 2017-12-31 | 18,552 | USD | 2019-03-14 | 10-K · 0001628280-19-002959 |
Related financial histories
- Bionano Genomics, Inc.: total assets
- Bionano Genomics, Inc.: total liabilities
- Bionano Genomics, Inc.: stockholders equity
- Bionano Genomics, Inc.: cash and cash equivalents
- Bionano Genomics, Inc.: net income or loss
- Bionano Genomics, Inc.: operating cash flow
- Bionano Genomics, Inc.: capital expenditure payments
- Bionano Genomics, Inc.: contract revenue excluding tax
- Bionano Genomics, Inc.: financing cash flow
- Bionano Genomics, Inc.: investing cash flow
- Bionano Genomics, Inc.: retained earnings or deficit
- Bionano Genomics, Inc.: basic weighted-average shares
- Bionano Genomics, Inc.: diluted weighted-average shares
- Bionano Genomics, Inc.: basic earnings per share
- Bionano Genomics, Inc.: diluted earnings per share
- Bionano Genomics, Inc.: net property, plant and equipment
- Bionano Genomics, Inc.: share-based compensation expense
- Bionano Genomics, Inc.: operating income or loss
- Bionano Genomics, Inc.: current assets
- Bionano Genomics, Inc.: interest expense
- Bionano Genomics, Inc.: current liabilities
- Bionano Genomics, Inc.: current accounts payable
- Bionano Genomics, Inc.: goodwill carrying amount
- Bionano Genomics, Inc.: net finite-lived intangible assets
- Bionano Genomics, Inc.: net current accounts receivable
- Bionano Genomics, Inc.: net inventory
- Bionano Genomics, Inc.: selling, general and administrative expense
- Bionano Genomics, Inc.: research and development expense
Inspect the source
- Entity
- Bionano Genomics, Inc. / CIK 0001411690
- Captured
- 2026-09-20T08:01:58.297Z
- SEC response SHA-256
de1f7683e64ca05fd1e6239a8009bb07a28d93e0115f74423aec0ba56b765b33
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001411690.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))